American Diabetes Association Launches 84th Scientific Sessions with Breakthrough Research

The upcoming 84th Scientific Sessions, organized by the American Diabetes Association (ADA), are set to take place in Orlando, FL, from June 21-24, 2024. This event is renowned as the premier global diabetes conference, drawing over 11,000 elite physicians, scientists, researchers, and healthcare professionals from around the globe. Attendees can expect an invigorating blend of in-person and virtual presentations, showcasing the latest in diabetes research and advancements.

Diabetes remains a significant health issue in the United States, ranking among the top ten causes of death. With over 1.4 million new cases each year, the prevalence of this condition has more than doubled over the past two decades due primarily to increased obesity rates, weight gain, and aging. This year's Scientific Sessions will spotlight the latest breakthroughs in diabetes research and care.

Some of the key topics to be addressed include:

Obesity and Weight-Loss Drugs: Obesity affects 42% of American adults and is responsible for up to 53% of new diabetes cases annually. The use of weight-loss medications has surged, with nearly two million Americans using semaglutide medications in 2021 — more than triple the number in 2019. The sessions will present numerous clinical studies on obesity treatments, focusing on glucagon-like peptide-1 (GLP-1) drugs and their effects on obesity, diabetes, sleep apnea, and kidney outcomes. Discussions will cover FDA-approved GLP-1 drugs like Tirzepatide and emerging candidates such as Retatrutide, Pemvidutide, and oral Ecnoglutide.

Technology and AI: Innovative technologies are revolutionizing diabetes management, paving the way for improved patient outcomes and personalized care. Studies will explore advancements in automated insulin delivery (AID) systems and continuous glucose monitors (CGMs), highlighting their impact on diabetes management.

Innovation: The Innovation Challenge, which debuted in 2023, will return on June 22 from 4:30-6:00 p.m. ET. This event invites emerging companies to present innovative ideas aimed at improving the lives of those living with diabetes. A panel of judges, along with input from a live audience, will select the winners, who will receive the opportunity to meet with potential investors.

Dr. Robert Gabbay, the ADA's chief scientific and medical officer, emphasized the importance of this event, stating, "As we commence the 84th Scientific Sessions, we are proud of our program that underscores our commitment to addressing the multifaceted challenges of diabetes. This year's program reflects our dedication to advancing research, fostering innovation, and ultimately improving the lives of those affected by diabetes. We look forward to an engaging and impactful event that will inspire and drive the future of diabetes care, at a pivotal time of pharmacological and technological advances in the field."

Other notable topics to be covered include eye health, health disparities, cancers related to diabetes and obesity, and early risk monitoring. The majority of sessions, including over 60 livestreamed ones, will be available on-demand for attendees until August 26.

Dr. Alice Y.Y. Cheng, chair of the 84th Scientific Sessions Planning Committee, highlighted the event's significance, saying, "This year's Scientific Sessions is set to highlight the latest and greatest advances in diabetes research with an exceptional, data-driven program. Whether you're joining us in-person or virtually, you'll have the opportunity to engage with leading experts, participate in dynamic discussions, and gain valuable insights that will drive the future of diabetes care."

Attendees will have access to detailed program navigation, educational session information, news updates, abstracts, and exhibitor details through the ADA Scientific Sessions mobile app and online planner.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!